Syon Capital LLC Makes New $403,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Syon Capital LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,548 shares of the medical research company's stock, valued at approximately $403,000.

A number of other large investors have also recently made changes to their positions in NTRA. Blue Trust Inc. boosted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc boosted its stake in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after buying an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its position in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. increased its holdings in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after buying an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Stock Performance

Natera stock traded down $4.39 during mid-day trading on Wednesday, hitting $150.50. The company had a trading volume of 285,674 shares, compared to its average volume of 1,375,220. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $92.01 and a 12-month high of $183.00. The company's fifty day moving average is $147.29 and its 200-day moving average is $153.88. The company has a market capitalization of $20.35 billion, a price-to-earnings ratio of -85.51 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other news, CFO Michael Burkes Brophy sold 495 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $150.74, for a total value of $74,616.30. Following the completion of the sale, the chief financial officer now directly owns 76,312 shares of the company's stock, valued at approximately $11,503,270.88. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the transaction, the chief executive officer now directly owns 203,354 shares in the company, valued at $29,160,963.60. The trade was a 30.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,080 shares of company stock valued at $26,473,363 in the last quarter. Corporate insiders own 7.60% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on NTRA shares. Robert W. Baird raised their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Royal Bank of Canada started coverage on shares of Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target for the company. Sanford C. Bernstein upped their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. Morgan Stanley increased their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Piper Sandler raised their price target on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and an average target price of $175.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.